Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Iontophoresis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    90 result(s) found for: Iontophoresis. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2008-003792-52 Sponsor Protocol Number: PAAI04 Start Date*: 2011-04-19
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik fuer Dermatologie
    Full Title: Azelaic acid iontophoresis versus topical azelaic acid cream in the treatment of melasma – An open randomized, controlled, prospective, single blinded clinical trial
    Medical condition: clinical diagnosis of melasma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002799-41 Sponsor Protocol Number: SHRTRM3 Start Date*: 2007-08-15
    Sponsor Name:Salford Royal Hospitals Trust [...]
    1. Salford Royal Hospitals Trust
    2. UNIVERSITY OF MANCHESTER
    Full Title: Iontophoresis as a possible therapy for digital ischaemia - preliminary studies in patients with scleroderma spectrum disorders
    Medical condition: Digital ischaemia/ulceration in patients with scleroderma-spectrum disorders
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004293-10 Sponsor Protocol Number: REH-TOX-2013-01 Start Date*: 2014-06-03
    Sponsor Name:Hospital Universitari de Tarragona Joan XXIII
    Full Title: Efficacy of treatment by iontophoresis of botulinum toxin type A free from complexing proteins for stump hyperhidrosis
    Medical condition: Stump hyperhidrosis in lower limb amputees
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008367-95 Sponsor Protocol Number: Kalani1 Start Date*: 2009-03-31
    Sponsor Name:Karolinska Institutet, Inst för kliniska vetenskaper, Danderyds sjukhus
    Full Title: Effect of exenatid on microcirculation in patients with type 2 diabetes mellitus and coronary artery disease
    Medical condition: Patients with type 2 diabetes and coronary artery disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001680-40 Sponsor Protocol Number: 000015 Start Date*: 2016-05-10
    Sponsor Name:Vestfold Hospital
    Full Title: Pilot study to evaluate the effect of instillation treatment with onabotulinumtoxin A (BOTOX®) in the urinary bladder using Electromotive Drug Application (EMDA) in women with overactive bladder.
    Medical condition: Overactive bladder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004624-11 Sponsor Protocol Number: Jonto01 Start Date*: 2019-03-13
    Sponsor Name:Region Östergötland
    Full Title: A non-randomized experimental study to optically study pharmacodynamic responses in the delivery of vasoactive substances to the skin through iontophoresis in healthy volunteers
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014643-36 Sponsor Protocol Number: MeBe/08/NEB-MICR/001 Start Date*: 2010-04-23
    Sponsor Name:MENARINI Benelux NV/SA
    Full Title: Effects Of The Administration Of Nebivolol Versus Carvedilol On Microcirculatory Endothelial Function, Arterial Stiffness And Wave Reflection In Healthy Volunteers” (NeCaMic-study)
    Medical condition: Microcirculatory Endothelial Function, Arterial Stiffness And Wave Reflection
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003775-21 Sponsor Protocol Number: ALH2 Start Date*: 2008-08-14
    Sponsor Name:Salford Royal Hospitals NHS Trust [...]
    1. Salford Royal Hospitals NHS Trust
    2. University of Manchester
    Full Title: Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis
    Medical condition: Systemic sclerosis (also termed 'scleroderma')
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003387-18 Sponsor Protocol Number: 2007CV23 Start Date*: 2008-12-08
    Sponsor Name:University of Dundee
    Full Title: The Effects of Oral Vitamin D Supplementation on Cardiovascular Disease Risk in UK South Asian Women
    Medical condition: Randomised, placebo controlled, parallel group, double blinded study to investigate if oral supplementation of vitamin D will improve cardiovascular function and metabolic and inflammatory paramete...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047066 Vascular disorders NEC HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000551-15 Sponsor Protocol Number: MTXa54 Start Date*: 2005-09-05
    Sponsor Name:University of Dundee
    Full Title: Effect of folic acid supplementation and allopurinol on endothelial function in patients with rheumatoid arthritis treated with methotrexate
    Medical condition: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory polyarthritis associated with excess cardiovascular (CV) mortality. Hyperhomocysteinaemia is recognized as an independent CV risk fact...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000396-26 Sponsor Protocol Number: EA-US-205-0111 Start Date*: 2015-02-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disea...
    Medical condition: Adult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004899-21 Sponsor Protocol Number: TR02-104 Start Date*: 2005-12-22
    Sponsor Name:Transave, Inc.
    Full Title: Safety and tolerability study of SLIT(TM) Amikacin 500 mg once daily for 14 days by inhalation in cystic fibrosis study subjects chronically infected with Pseudomonas aeruginosa.
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004389-17 Sponsor Protocol Number: TR02-103 Start Date*: 2005-12-28
    Sponsor Name:Transave, Inc
    Full Title: SAFETY AND TOLERABILITY STUDY OF SLIT AMIKACIN 500 MG ONCE DAILY FOR 14 DAYS BY INHALATION IN CYSTIC FIBROSIS STUDY SUBJECTS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA
    Medical condition: Cystic Fibrosis with mild to moderate obstructive lung disease and chronic infection with Pseudomonas aeruginosa
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-001438-34 Sponsor Protocol Number: 20-101 Start Date*: 2005-05-23
    Sponsor Name:McNeil Consumer and Specialty Pharmaceuticals
    Full Title: A Phase II, Randomized, Investigator-Blinded, Parallel-Group, Pilot Study Evaluating the Safety, Palatability and Efficacy of Four Doses of Pancrelipase Microtablets in the Treatment of Infants and...
    Medical condition: Cystic Fibrosis-Related Pancreatic Insufficiency and Fat Malabsorption
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000279-26 Sponsor Protocol Number: 56536 Start Date*: 2017-03-07
    Sponsor Name:Erasmus MC
    Full Title: Trigeminovascular effects of propranolol in migraine treatment
    Medical condition: Healthy Volunteers (Migraine)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005256-34 Sponsor Protocol Number: 38589 Start Date*: 2012-10-29
    Sponsor Name:Erasmus MC
    Full Title: Sumatriptan non-responders: evaluation of a possible biomarker
    Medical condition: Healthy Volunteers (Migraine)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004344-30 Sponsor Protocol Number: Moli1901-010A Start Date*: 2005-10-31
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease
    Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-000261-21 Sponsor Protocol Number: 1399-0003 Start Date*: 2019-10-08
    Sponsor Name:Boehringer Ingelheim
    Full Title: A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy t...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000178-21 Sponsor Protocol Number: 0000767 Start Date*: Information not available in EudraCT
    Sponsor Name:Altus Pharmaceuticals Inc.
    Full Title: An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Medical condition: Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011765 Cystic fibrosis pancreas LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000844-13 Sponsor Protocol Number: SMR-2984 Start Date*: 2014-09-25
    Sponsor Name:Algipharma AS
    Full Title: A double-blind, randomized, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:42:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA